Arovella Therapeutics Ltd (ASX: ALA) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Arovella Therapeutics Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$89.33 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
1.21 billion
Earnings per share
-0.007
Dividend per share
N/A
Year To Date Return
-20.43%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Arovella Therapeutics Ltd (ASX: ALA)
Latest News
Share Market News
Suda Pharmaceuticals share price soars 200% on TGA approval
ALA ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Arovella Therapeutics Ltd
Arovella Therapeutics Ltd is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours. The company's lead iNKT cell product is ALA-101. ALA-101 consists of iNKT cells engineered to produce a Chimeric Antigen Receptor (CAR) targeting CD19 on their surface. This CD19-targeting CAR allows the iNKT cells to find and kill tumour cells that express CD19.
ALA Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 13 Mar 2026 | $0.07 | $0.00 | 0.00% | 122,465 | $0.08 | $0.08 | $0.07 |
| 12 Mar 2026 | $0.08 | $0.00 | 0.00% | 264,676 | $0.08 | $0.08 | $0.07 |
| 11 Mar 2026 | $0.08 | $0.00 | 0.00% | 224,508 | $0.08 | $0.08 | $0.08 |
| 10 Mar 2026 | $0.08 | $0.00 | 0.00% | 209,294 | $0.07 | $0.08 | $0.07 |
| 09 Mar 2026 | $0.07 | $0.00 | 0.00% | 1,862,560 | $0.08 | $0.08 | $0.07 |
| 06 Mar 2026 | $0.08 | $0.00 | 0.00% | 373,156 | $0.08 | $0.08 | $0.08 |
| 05 Mar 2026 | $0.08 | $0.00 | 0.00% | 925,018 | $0.08 | $0.08 | $0.08 |
| 04 Mar 2026 | $0.08 | $0.00 | 0.00% | 395,197 | $0.08 | $0.08 | $0.08 |
| 03 Mar 2026 | $0.08 | $0.00 | 0.00% | 148,799 | $0.08 | $0.08 | $0.08 |
| 02 Mar 2026 | $0.08 | $0.00 | 0.00% | 686,610 | $0.08 | $0.08 | $0.08 |
| 27 Feb 2026 | $0.08 | $0.00 | 0.00% | 935,109 | $0.09 | $0.09 | $0.08 |
| 26 Feb 2026 | $0.08 | $0.00 | 0.00% | 243,430 | $0.09 | $0.09 | $0.08 |
| 25 Feb 2026 | $0.09 | $0.00 | 0.00% | 549,694 | $0.09 | $0.09 | $0.09 |
| 24 Feb 2026 | $0.09 | $0.00 | 0.00% | 531,248 | $0.09 | $0.09 | $0.09 |
| 23 Feb 2026 | $0.09 | $0.00 | 0.00% | 951,826 | $0.09 | $0.09 | $0.09 |
| 20 Feb 2026 | $0.09 | $0.00 | 0.00% | 771,235 | $0.09 | $0.09 | $0.09 |
| 19 Feb 2026 | $0.09 | $0.00 | 0.00% | 834,532 | $0.09 | $0.09 | $0.09 |
| 18 Feb 2026 | $0.09 | $0.00 | 0.00% | 927,670 | $0.09 | $0.09 | $0.08 |
| 17 Feb 2026 | $0.09 | $-0.01 | -10.75% | 2,267,952 | $0.09 | $0.10 | $0.08 |
| 16 Feb 2026 | $0.09 | $0.00 | 0.00% | 721,590 | $0.09 | $0.09 | $0.09 |
| 13 Feb 2026 | $0.09 | $0.00 | 0.00% | 84,148 | $0.09 | $0.10 | $0.09 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 24 Nov 2025 | Elizabeth Stoner | Expiry | 1,242,353 | $103,115 |
Options expired.
|
| 24 Nov 2025 | Elizabeth Stoner | Exercise | 1,157,647 | $96,084 |
Exercise of options.
|
| 24 Nov 2025 | Elizabeth Stoner | Buy | 1,157,647 | $96,084 |
Exercise of options.
|
| 12 Nov 2025 | Debora Barton | Exercise | 1,013,333 | $52,693 |
Exercise of options.
|
| 12 Nov 2025 | Debora Barton | Expiry | 1,386,667 | $133,120 |
Options expired.
|
| 12 Nov 2025 | Debora Barton | Buy | 1,013,333 | $97,279 |
Exercise of options.
|
| 10 Nov 2025 | Gary Phillips | Issued | 1,160,000 | $103,240 |
Issue of options.
|
| 10 Nov 2025 | Michael Baker | Issued | 1,831,266 | $162,982 |
Issue of options.
|
| 13 Oct 2025 | Michael Baker | Exercise | 1,617,021 | $121,276 |
Exercise of options.
|
| 13 Oct 2025 | Michael Baker | Issued | 1,617,021 | $121,276 |
Exercise of options.
|
| 13 Oct 2025 | Michael Baker | Expiry | 6,382,979 | $600,000 |
Options expired.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Dr Andrew Nash | Non-Executive Director | Nov 2025 |
Dr Nash has over 35 years of practical drug development experience and executive leadership in the biotech and pharmaceutical sector. Dr Nash initially trained as an academic scientist. He then joined Zenyth (formerly Amrad Corp), where he advanced to become Chief Scientific Officer (CSO), and ultimately CEO before it was sold to CSL in 2006. Dr Nash was appointed CSO of CSL in 2020 and remained in that position until his retirement in March 2025. Dr Nash has had a career, being elected as a Fellow of the Academy of Technological Sciences and Engineering in 2021, and as a Fellow of the Australian Academy of Science in 2025. He was the inaugural Chair of Jumar Bioincubator and is currently a Board Director at the Burnet Institute, the Garvan Institute of Medical Research, Brandon BioCatalyst and Denteric.
|
| Dr Michael Baker | Chief Executive OfficerManaging Director | Jan 2020 |
Dr Baker has over 20 years of experience in scientific research, drug development and venture investment. He was an Investment Manager with Australian life science fund, BioScience Managers, responsible for deal sourcing from networks, conferences, universities, and research institutes. He also conducted due diligence to shortlist investment opportunities and played an active role in managing portfolio companies.
|
| Dr Debora Barton | Non-Executive Director | Aug 2021 |
Dr Barton has over 20 years of oncology experience, which includes 9 years of clinical management of oncology patients and enrolling patients in clinical trials in academia. In the pharmaceutical industry, she has experience in medical affairs and clinical development in both large pharmaceutical and small biotech companies, including regulatory interactions in the USA, Europe, Australia, and several countries around the world. She has undertaken an oncology product submission and subsequent marketing authorisation in the US and Europe and has built innovative clinical development plans coupled with clinical/safety teams' infrastructure in small biotech.
|
| Mr Lachie Mallia | Chief Financial OfficerCompany Secretary | Jan 2026 |
-
|
| Lachie Mallia | Chief Financial OfficerCompany Secretary |
-
|
|
| Dr. Nicole van der Weerden | Chief Operating Officer |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Merchant Funds Management | 68,677,966 | 5.78% |
| Richard John Mann | 68,487,674 | 5.76% |
| Netwealth Investments Limited Wrap Services A/C | 32,788,389 | 2.76% |
| Netwealth Investments Limited Super Services A/C | 30,519,572 | 2.57% |
| UBS Nominees Pty Ltd | 29,070,196 | 2.45% |
| MB Investment Capital Pty Ltd | 27,749,415 | 2.33% |
| Blackburne Capital Pty Ltd Blackburne Capital A/C | 23,008,988 | 1.94% |
| Ajava Holdings Pty Ltd | 23,000,000 | 1.94% |
| Mr James Evan Hughes Morris | 18,857,522 | 1.59% |
| Legacy Asset Holdings Pty Ltd | 18,693,494 | 1.57% |
| DP Investment Capital Pty Ltd | 18,000,000 | 1.51% |
| Dylide Pty Ltd | 16,227,481 | 1.37% |
| M & M Stock One Pty Ltd The M & M Stock One A/C | 15,087,106 | 1.27% |
| Mr Neil Donald Delroy Ndd Investment A/C | 14,167,222 | 1.19% |
| J P Morgan Nominees Australia Pty Limited | 13,234,438 | 1.11% |
| BNP Paribas Noms Pty Ltd | 12,029,212 | 1.01% |
| Moovnup Pty Ltd Moovnup A/C | 11,593,075 | 0.98% |
| Widerange Corporation Pty Ltd | 10,390,789 | 0.87% |
| Citicorp Nominees Pty Limited | 9,677,162 | 0.81% |
| Mr Brendan John Martin & Mrs Sharon Ann Martin Jaknic Super A/C | 9,564,970 | 0.80% |